Mirati Therapeutics

Website:mirati.com
Location:San Diego, CA United States
Revenue:$12.9M
Industry:Biotech
Founded:2013
Lead Investor(s):Cowen, Barclays
Press

Current Growjo Ranking

City Ranking

Industry Ranking

State Ranking

Growjo 10k Ranking

Mirati Therapeutics develops molecularly targeted, single agent and immuno-oncology combination therapies intended to treat cancer. Mirati's approach combines the three most important factors in oncology drug development, 1) researching and developing drug candidates that target genetic and epigenetic drivers of cancer, 2) designing creative and agile clinical development strategies that select for patients whose tumors are dependent on specific driver alterations, and 3) leveraging a highly accomplished oncology precision medicine leadership team. The Mirati team uses a blueprint - proven by their prior work - for developing potential breakthrough cancer therapies, with accelerated development paths, in order to improve outcomes for patients. Mirati is advancing three drug candidates through clinical development for multiple oncology indications.

keywords:Biotechnology,Healthcare,Marketing,Pharmaceuticals

69

Number of Employees

$12.9M

Revenue (est)

9

Current Jobs

33%

Employee Growth %

$101.3M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Mirati Therapeutics News

20-Mar-19 - Mirati Therapeutics (MRTX) Hits New 52-Week High at $80.00

Mirati Therapeutics Inc (NASDAQ:MRTX)'s share price reached a new 52-week high on Monday . The stock traded as high as $80.00 and last

20-Mar-19 - 2 Hot Stocks For Today: Mirati Therapeutics, Inc. (MRTX), AmeriGas

Mirati Therapeutics, Inc. (NASDAQ:MRTX) shares ended at $76.31 with 1.09 mln shares exchanging hands. That puts the market capitalization

28-Feb-19 - Mirati Therapeutics Reports Fourth Quarter Financial Results

28, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial

Mirati Therapeutics Funding

DateAmountRoundLead InvestorsReference
2013-10-17$UndisclosedUndisclosedLeerink Swann LLCArticle
2013-10-24$56.9MUndisclosedJefferies LLCArticle
2015-09-15$80.0MUndisclosedCitigroupArticle
2015-09-16$101.3MUndisclosedCitigroupArticle
2017-01-09$65.0MUndisclosedLeerink PartnersArticle
2017-11-21$92.0MUndisclosedCowenArticle
2018-06-12$139.2MUndisclosedCowenArticle
2019-01-17$115.0MUndisclosedMultipleArticle
2019-01-23$130.0MUndisclosedMultipleArticle

Mirati Therapeutics Executive Hires

DateNameTitleReference
2016-01-11Marcy GrahamVP Investor Relations/Corporate CommunicationsArticle
2016-03-24Jamie DonadioSVP/CFOArticle
2016-10-05Chris LeMastersExecutive Vice President/Chief Business OfficerArticle